Growth Metrics

AbCellera Biologics (ABCL) Short term Debt (2020 - 2025)

AbCellera Biologics filings provide 6 years of Short term Debt readings, the most recent being $8.8 million for Q1 2025.

  • Quarterly Short term Debt fell 82.95% to $8.8 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Mar 2025, down 82.95% year-over-year, with the annual reading at $8.1 million for FY2024, 83.98% down from the prior year.
  • Short term Debt hit $8.8 million in Q1 2025 for AbCellera Biologics, up from $8.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $54.9 million in Q2 2023 and bottomed at $8.1 million in Q4 2024.
  • Average Short term Debt over 5 years is $30.0 million, with a median of $27.5 million recorded in 2022.
  • The largest annual shift saw Short term Debt skyrocketed 195.99% in 2022 before it plummeted 83.98% in 2024.
  • AbCellera Biologics' Short term Debt stood at $22.9 million in 2021, then surged by 92.77% to $44.2 million in 2022, then rose by 14.17% to $50.5 million in 2023, then plummeted by 83.98% to $8.1 million in 2024, then grew by 8.46% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Short term Debt are $8.8 million (Q1 2025), $8.1 million (Q4 2024), and $20.2 million (Q3 2024).